Rachel Airley

1.7k total citations
22 papers, 1.4k citations indexed

About

Rachel Airley is a scholar working on Cancer Research, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Rachel Airley has authored 22 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cancer Research, 12 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rachel Airley's work include Cancer, Hypoxia, and Metabolism (15 papers), Metabolism, Diabetes, and Cancer (6 papers) and RNA modifications and cancer (3 papers). Rachel Airley is often cited by papers focused on Cancer, Hypoxia, and Metabolism (15 papers), Metabolism, Diabetes, and Cancer (6 papers) and RNA modifications and cancer (3 papers). Rachel Airley collaborates with scholars based in United Kingdom, United States and Netherlands. Rachel Airley's co-authors include Ali Mobasheri, Ian J. Stratford, Catharine West, J. Loncaster, S.E. Davidson, Stephen M. Hewitt, Adam V. Patterson, Adrian L. Harris, Stephen K. Roberts and Michael Bromley and has published in prestigious journals such as Oncogene, British Journal of Cancer and International Journal of Cancer.

In The Last Decade

Rachel Airley

21 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rachel Airley United Kingdom 16 866 826 276 200 155 22 1.4k
Amen Sibtain United Kingdom 11 730 0.8× 1.0k 1.2× 333 1.2× 233 1.2× 230 1.5× 21 1.7k
Michael I. Koukourakis Greece 15 594 0.7× 831 1.0× 297 1.1× 228 1.1× 113 0.7× 21 1.4k
Robert Lemos United States 15 531 0.6× 878 1.1× 438 1.6× 207 1.0× 103 0.7× 20 1.4k
Margaret Willard United States 10 719 0.8× 1.0k 1.2× 438 1.6× 172 0.9× 65 0.4× 12 1.7k
Mary J. Dorie United States 23 846 1.0× 978 1.2× 611 2.2× 218 1.1× 58 0.4× 34 1.9k
Fernando Doñate United States 22 341 0.4× 897 1.1× 508 1.8× 145 0.7× 152 1.0× 56 1.8k
Jessica E.S. Shay United States 11 932 1.1× 903 1.1× 183 0.7× 128 0.6× 87 0.6× 22 1.5k
Cheng Han United Kingdom 19 722 0.8× 959 1.2× 459 1.7× 180 0.9× 95 0.6× 21 1.6k
Reinhard von Roemeling United States 23 606 0.7× 774 0.9× 728 2.6× 626 3.1× 212 1.4× 72 2.0k
Mikael Johansson Sweden 20 619 0.7× 826 1.0× 483 1.8× 449 2.2× 215 1.4× 44 1.8k

Countries citing papers authored by Rachel Airley

Since Specialization
Citations

This map shows the geographic impact of Rachel Airley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel Airley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel Airley more than expected).

Fields of papers citing papers by Rachel Airley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel Airley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel Airley. The network helps show where Rachel Airley may publish in the future.

Co-authorship network of co-authors of Rachel Airley

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel Airley. A scholar is included among the top collaborators of Rachel Airley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel Airley. Rachel Airley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pujol‐Giménez, Jonai, Fátima Pérez de Heredia, Miguel Á. Idoate, et al.. (2015). Could GLUT12 be a Potential Therapeutic Target in Cancer Treatment? A Preliminary Report. Journal of Cancer. 6(2). 139–143. 27 indexed citations
2.
Hemming, K., et al.. (2014). Azide based routes to tetrazolo and oxadiazolo derivatives of pyrrolobenzodiazepines and pyrrolobenzothiadiazepines. Tetrahedron. 70(40). 7306–7317. 6 indexed citations
3.
Airley, Rachel, Patrick McHugh, Andrew R. Evans, et al.. (2013). Role of carbohydrate response element-binding protein (ChREBP) in generating an aerobic metabolic phenotype and in breast cancer progression. British Journal of Cancer. 110(3). 715–723. 32 indexed citations
4.
Airley, Rachel & Andy Evans. (2012). How The Science Of Personalized Medicines Will Change The Clinical Management Of Patients In The Pharmacy. Future Medicinal Chemistry. 4(16). 2023–2027. 1 indexed citations
5.
Airley, Rachel. (2012). Lab Reports And Cat Scans: Can Veterinary Oncology Guide Our Way To New Treatments For Human Cancers?. Future Medicinal Chemistry. 4(11). 1391–1394. 5 indexed citations
6.
Troy, Helen, Yuen‐Li Chung, Paul M.J. McSheehy, et al.. (2011). Adaptation to HIF-1 deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase activation in hepatomas. BMC Cancer. 11(1). 198–198. 24 indexed citations
7.
Airley, Rachel, Andrew R. Evans, Ali Mobasheri, & Stephen M. Hewitt. (2010). Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: Study using tissue microarrays. Annals of Anatomy - Anatomischer Anzeiger. 192(3). 133–138. 49 indexed citations
8.
Airley, Rachel & Ali Mobasheri. (2007). Hypoxic Regulation of Glucose Transport, Anaerobic Metabolism and Angiogenesis in Cancer: Novel Pathways and Targets for Anticancer Therapeutics. Chemotherapy. 53(4). 233–256. 283 indexed citations
9.
Evans, Andrew R., Helen Troy, Stephen M. Hewitt, et al.. (2007). Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemotherapy and Pharmacology. 61(3). 377–393. 70 indexed citations
10.
Mobasheri, Ali, Rachel Airley, Stephen M. Hewitt, & David Marples. (2005). Heterogeneous expression of the aquaporin 1 (AQP1) water channel in tumors of the prostate, breast, ovary, colon and lung: A study using high density multiple human tumor tissue microarrays. International Journal of Oncology. 26(5). 1149–58. 85 indexed citations
11.
12.
Mobasheri, Ali, Rachel Airley, Christopher S. Foster, Gundula Schulze‐Tanzil, & Mehdi Shakibaei. (2004). Post-genomic applications of tissue microarrays: basic research, prognostic oncology, clinical genomics and drug discovery.. PubMed. 19(1). 325–35. 32 indexed citations
13.
Oliver, Richard, et al.. (2004). Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection. European Journal of Cancer. 40(4). 503–507. 69 indexed citations
14.
Cowen, Rachel, Adam V. Patterson, Brian A. Telfer, et al.. (2003). Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts.. PubMed. 2(9). 901–9. 31 indexed citations
15.
Airley, Rachel, J. Loncaster, James A. Raleigh, et al.. (2003). GLUT‐1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding. International Journal of Cancer. 104(1). 85–91. 184 indexed citations
16.
Cooper, Rachel, Sülen Sarıoğlu, Selman Sökmen, et al.. (2003). Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma?. British Journal of Cancer. 89(5). 870–876. 92 indexed citations
17.
Patterson, Adam V., R. Cowen, Brian A. Telfer, et al.. (2002). Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Therapy. 9(14). 946–954. 47 indexed citations
18.
Williams, Kaye J., Brian A. Telfer, Rachel Airley, et al.. (2002). A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis. Oncogene. 21(2). 282–290. 70 indexed citations
19.
Airley, Rachel, et al.. (2002). An evaluation of the impact of NICE guidelines regarding COX-2 selective inhibitors on GP prescribing. International Journal of Pharmacy Practice. 10(Supplement_1). R78–R78.
20.
Airley, Rachel, et al.. (2000). Hypoxia and disease: opportunities for novel diagnostic and therapeutic prodrug strategies. University of Huddersfield Repository (University of Huddersfield). 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Amen Sibtain Breakdown of academic impact, for papers by Michael I. Koukourakis Breakdown of academic impact, for papers by Robert Lemos Breakdown of academic impact, for papers by Margaret Willard Breakdown of academic impact, for papers by Mary J. Dorie Breakdown of academic impact, for papers by Fernando Doñate Breakdown of academic impact, for papers by Jessica E.S. Shay Breakdown of academic impact, for papers by Cheng Han Breakdown of academic impact, for papers by Reinhard von Roemeling Breakdown of academic impact, for papers by Mikael Johansson
Rankless by CCL
2026